Stock Quote

ACOR (Common Stock) $ 35.12 -0.75 (-2.09%) Volume: 934,720 MORE April 15, 2014

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *






Corporate Governance

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.

Acorda markets three FDA-approved therapies including:  AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg,  a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia.  AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.

Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure.

Governance Documents

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.

Chairperson Member Financial Expert
  Audit Commitee Compensation Commitee Compliance Commitee Nominations & Governance Commitee
Barry Greene    
Peder Jensen    
John Kelley    
Sandra Panem, Ph.D.    
Lorin J. Randall  
Steven M. Rauscher      
Ian F. Smith